Intravitreal combination of triamcinolone acetonide and bevacizumab (Kenacort-Avastin) in diffuse diabetic macular edema.

Miltiadis K Tsilimbaris, Vassilios Pandeleondidis, Theoni Panagiototglou, Vassiliki Arvanitaki, Sofia Fragiskou, Maria Eleftheriadou, Chrysanthi Tsika, Theokliti Papadaki

Journal: Seminars in ophthalmology 2010;24(6):225-30

PMID: 19954371

Full Text on Atypon View on PubMed

Abstract

PURPOSE

To evaluate the effect of intravitreal injection of the combination of Triamcinolone Acetonide and Bevacizumab in patients with diabetic macular edema.

MATERIALS AND METHODS

Twenty seven eyes of 17 patients with diabetic macular edema were treated with an intravitreal injection of triamcinolone acetonide (2 mg) combined with bevacizumab (1.25 mg).

RESULTS

During the 6 months follow-up period 24 eyes (89%) had to repeat the treatment according to the monthly follow-up examination.The mean visual acuity and the central macular thickness improved significantly (P<0.05) throughout the follow-up period.

CONCLUSION

Intravitreal combination of Triamcinolone Acetonide and Bevacizumab seems to be effective in improving visual acuity and macular edema in patients with diabetic maculopathy.

Address: Retina Service, University Eye Clinic of Heraklion, Crete, Greece. [email protected]

DOI: 10.3109/08820530903389775

Link outs

Free resources

Medical:

https://medlineplus.gov/diabeticeyeproblems.html

Subscription / membership required

Full Text Sources:

https://www.tandfonline.com/doi/10.3109/0882053090...

MeSH Terms: Aged, Angiogenesis Inhibitors, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Bevacizumab, Diabetic Retinopathy, Drug Combinations, Female, Humans, Immunosuppressive Agents, Injections, Intraocular, Macula Lutea, Macular Edema, Male, Middle Aged, Prospective Studies, Triamcinolone Acetonide, Visual Acuity